Applied DNA Sciences, Inc. (NASDAQ:BNBX) — Stock Price
Applied DNA Sciences, Inc. (NASDAQ:BNBX) is currently trading at $0.14 USD, down 15.50% today. Over the past 52 weeks, shares have ranged between $0.07 and $4.80. This page tracks Applied DNA Sciences, Inc.'s live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see BNBX stock market capitalisation.
Applied DNA Sciences, Inc. (BNBX) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Applied DNA Sciences, Inc.'s daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Applied DNA Sciences, Inc. Income Statement — Revenue, Profit & Earnings by Year
Applied DNA Sciences, Inc.'s annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $2.14 Million | $3.43 Million | $13.37 Million | $18.17 Million | $9.03 Million |
| Cost of Revenue | $1.30 Million | $2.41 Million | $7.83 Million | $13.12 Million | $4.54 Million |
| Gross Profit | $838.91K | $1.02 Million | $5.53 Million | $5.05 Million | $4.48 Million |
| Research & Development | $6.02 Million | $3.59 Million | $3.74 Million | $3.93 Million | $4.16 Million |
| SG&A | $10.87 Million | $11.45 Million | $12.75 Million | $15.10 Million | $12.85 Million |
| Total Operating Expenses | $16.89 Million | $15.04 Million | $16.49 Million | $19.02 Million | $17.83 Million |
| Operating Income | $-16.05 Million | $-14.02 Million | $-10.95 Million | $-13.97 Million | $-13.35 Million |
| EBITDA | $-15.66 Million | $-13.33 Million | $-9.59 Million | $-12.68 Million | $-11.68 Million |
| EBIT | $-16.05 Million | $-14.02 Million | $-10.95 Million | $-13.97 Million | $-12.53 Million |
| Interest Expense | — | — | — | — | — |
| Income Before Tax | $-15.64 Million | $-7.09 Million | $-10.02 Million | $-8.27 Million | $-14.28 Million |
| Income Tax Expense | $-684.12K | — | — | — | — |
| Net Income | $-15.16 Million | $-6.99 Million | $-9.95 Million | $-8.27 Million | $-14.29 Million |
Applied DNA Sciences, Inc. Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Applied DNA Sciences, Inc.'s financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $4.44 Million | $12.79 Million | $13.65 Million | $22.27 Million | $14.42 Million |
| Total Current Assets | $2.24 Million | $8.05 Million | $8.13 Million | $19.94 Million | $11.30 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | $237.40K | $362.01K | $255.50K | $3.07 Million | $2.80 Million |
| Inventory | $84.10K | $438.59K | $330.03K | $602.24K | $1.37 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $2.50 Million | $3.82 Million | $8.78 Million | $9.36 Million | $3.30 Million |
| Total Current Liabilities | $2.46 Million | $2.40 Million | $2.85 Million | $4.19 Million | $3.27 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $-1.47 Million | $-5.69 Million | $-5.91 Million | $-15.22 Million | $-6.55 Million |
| Total Stockholder Equity | $2.30 Million | $9.14 Million | $4.95 Million | $12.91 Million | $11.11 Million |
| Retained Earnings | $-379.16 Million | $-309.67 Million | $-302.45 Million | $-292.50 Million | $-284.12 Million |
Applied DNA Sciences, Inc. Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Applied DNA Sciences, Inc. generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-12.52 Million | $-13.71 Million | $-6.22 Million | $-8.98 Million | $-13.39 Million |
| Capital Expenditures | $313.12K | $407.90K | $78.45K | $489.55K | $2.55 Million |
| Free Cash Flow | $-12.83 Million | $-14.12 Million | $-6.30 Million | $-9.47 Million | $-15.94 Million |
| Investing Cash Flow | $-292.12K | — | — | — | — |
| Financing Cash Flow | $8.05 Million | $13.40 Million | $0.00 | $18.13 Million | $14.70 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $102.02K | $572.29K | $1.03 Million | $2.52 Million | $1.67 Million |
| Depreciation | $384.17K | $696.42K | $1.36 Million | $1.29 Million | $844.44K |
| Change in Cash | $-4.76 Million | $-720.71K | $-7.31 Million | $8.66 Million | $-1.23 Million |
Applied DNA Sciences, Inc. Earnings History — EPS Actual vs. Analyst Estimates
Track Applied DNA Sciences, Inc.'s quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 29, 2026 | -0.68 | — | — |
| Feb 27, 2026 | -2.08 | — | — |
| Aug 14, 2025 | 20.79 | -37.50 | +155.44% |
| May 15, 2025 | -230.31 | -45.00 | -411.80% |
| Feb 13, 2025 | -27.84 | -0.31 | -8880.65% |
| Dec 18, 2024 | -240.01 | — | — |
| Aug 08, 2024 | 0.47 | -3.70 | +112.70% |
| May 09, 2024 | -3981.73 | -4.50 | -88382.79% |